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The roles of non-coding RNAs in cancers, microRNA (miRNA) especially, have sparked interest in the field of 
RNA research in recent years. The once widely accepted ‘central dogma of genetics’ describing the flow of 
cellular protein expression is now being challenged following the discovery of non-coding RNA research. 
miRNAs belong to the family of non-coding RNAs, in which many have been shown to be involved in cancer 
progression, including breast cancer. Goh et al. have recently summarized comprehensively, the roles played by 
miRNAs in the hallmarks of breast cancer progression. In this research highlight, we provide a brief summary 
of these miRNA-associated hallmarks in breast cancer progression and also highlight DEAD-box RNA helicases, 
a family of proteins known to be associated with miRNA-associated tumorigenesis. There are an increasing 
number of studies on DEAD-box RNA helicases in recent years, with different roles being reported in numerous 
cancer types. DDX20, a member of the DEAD-box RNA helicase family, was most recently revealed to be 
involved in breast cancer progression and metastasis. New data from our group found a possible novel 
miRNA-processing role of DDX20 in breast cancer. In an ongoing study, we found that miR-222 expression 
inversely correlates with DDX20, suggesting a possible tumor-suppressing role of miR-222 in invasive breast 
cancers, contrary to previous reports where miR-222 was associated with invasion in breast cancers. Our work 
thus provides another dimension to the complexity, where miRNAs and DEAD-box RNA helicases play in breast 
cancers. 
To cite this article: Wanpei Cai, et al. DEAD-box RNA Helicases: The microRNA managers of breast cancer. RNA Dis 
2015; 2: e846. doi: 10.14800/rd.846. 
Cancer arises as a result of dynamic changes to the 
genome, producing oncogenes and repressing of tumor 
suppressors. Such non-specific insults to the genome lead to 
the heterogeneity of cancers, including breast cancers. Breast 
cancer can be classified into various molecular subtypes, 
hormone receptor-positive luminal subtype, HER2 
receptor-enriched subtype and triple negative breast cancer 
subtype (TNBC) [1]. The treatment of triple negative breast 
cancers (TNBC) remains challenging due to the lack of 
therapeutic targets. Gene expression analysis from 587 
TNBC cases showed TNBCs to be highly diverse, indicating 
a need to better understand the disease and identify specific 
REVIEW 
RNA & DISEASE 2015; 2: e846. doi: 10.14800/rd.846; © 2015 by Wanpei Cai, et al. 
http://www.smartscitech.com/index.php/rd 
 
Page 2 of 6 
 
biomarkers for targeted therapies [2].  
Over the past decades, a growing number of studies have 
focused on the involvement of miRNAs in various diseases, 
including cancers [3, 4]. miRNAs are non-coding small RNAs, 
which regulate gene expression post-transcriptionally by 
binding to the 3’-UTR of target mRNAs. miRNAs regulate a 
wide range of important cellular processes, including 
proliferation, apoptosis, immune response and metabolism 
[5]. In cancers, including breast cancer, miRNAs are reported 
to be dysregulated [6, 7], and miRNA profiling has shown that 
tumor samples exhibit lower global miRNA level compared 
with normal tissues [8]. Due to the extensive dysregulation of 
miRNAs in cancers, miRNA profiles can provide valuable 
diagnostic and prognostic information. In addition, numerous 
studies have reported pivotal functions of miRNAs in the 
hallmarks of cancers, summarized in a recent review by Goh 
et al. [5, 9, 10]. Hanahan D et al. described the acquired 
capabilities of cancers as six hallmarks, including sustaining 
proliferative signals, insensitivity to anti-growth signals, 
evasion of apoptosis, infinite replicative potential, sustained 
angiogenesis, and invasion and metastasis [11]. Over a 
decade’s time, reprogrammed energy metabolism and 
evasion of immune system have added to the emerging 
cancer hallmarks [12]. 
Dysregulation of cell proliferation is one of the crucial 
characteristics of cancer. Numerous mitogenic growth 
signals and anti-proliferative signals contribute to the 
regulation of cell proliferation. Many studies have suggested 
that miRNAs regulate cell proliferation through various 
pathways, with some miRNAs promoting oncogenic signals 
and others inhibiting tumor suppressing signals. miR-107 and 
miR-206 have been found to interact with cell cycle 
regulators to regulate cell cycle progression and the 
expression of cell cycle related proteins, while miR-24 and 
miR-100, involved in cell survival signaling [13-16]. In breast 
cancers, estrogen receptor (ER) signaling is also indirectly 
regulated by miRNAs such as miR-17-5p [17]. 
In addition to regulating cell growth, miRNAs also play 
critical roles in apoptosis by targeting mRNAs to regulate the 
expression of pro and anti-apoptosis proteins. 
Tumor-suppressing miRNAs (tsmiRNAs), such as miR-34a 
and miR-195, inhibit the expression of oncogenes Bcl-2, 
MYC or Raf-1 etc, while oncogenic miRNAs associate with 
upregulation of pro-apoptotic proteins [18, 19]. However, 
certain miRNAs, miR-26a as an example, exert either 
oncogenic or tumor suppressing effects in a 
context-dependent manner [20, 21]. In chemo-resistant cancer 
cells, manipulation of miRNAs can increase their sensitivity 
to chemotherapeutic drugs; miR-128 and miR-26b target Bax 
and SLC7A11 respectively to induce apoptosis in breast 
cancer cells [22, 23]. 
Cancer cells are known to evade immune attacks through 
many signaling pathways, and accumulating studies have 
demonstrated that miRNAs are involved in the immune 
responses in cancers. miR-10b and miR-155 have been 
reported to be both oncogenic and inflammatory responsive 
by inhibiting major histocompatibility complex Class I 
polypeptide-related sequence B (MICB) or enhancing 
suppressor of cytokine signaling 1 (SOCS1), respectively [24, 
25]. Another important link between inflammation and 
cancers is M2-polarized tumor-associated macrophages, 
which have been shown to contribute to cancer progression 
and epithelial-mesenchymal transition (EMT) [26]. miR-92a 
was found to inversely correlate to infiltrating macrophages 
in tumor stroma and down-regulation of miR-92a enhanced 
tumor migration [27]. 
Metastasis is the main cause of cancer related deaths. 
There are numerous proteins and pathways discovered to 
drive metastasis in cancers, and miRNAs are found to target 
important metastasis regulators to either promote or suppress 
metastasis. miR-183 cluster members, miR-182 and miR-96, 
target tumor suppressor RECK, a matrix metalloproteinase 
inhibitor, to increase invasiveness [28, 29]. Negative regulators 
of Wnt/ß-catenin pathway are suppressed by miR-301a and 
miR-374a to promote breast cancer invasion and metastasis 
[30, 31]. miR-200 family is known to be the negative regulators 
of metastasis by inhibiting EMT and tumor cell migration 
[32].  
The dysregulated metabolism of cancer cells has been 
studied for many decades, with examples such as RAS and 
TP53 being discovered to be important modulators.  
However, it is until recently that an increasing number of 
studies associating miRNAs with cancer metabolism have 
been carried out. In normal breast cells, miR-203 was 
uncovered to inversely correlate with caveolin-1, whose loss 
was found to fuel the growth of tumor cells [33]. In breast 
cancer, miR-378* was reported to be regulated by HER2 and 
lead to a metabolic change in breast cancers cells via 
blocking estrogen-related receptor gamma (ERRγ) and 
GA-binding protein alpha (GABPA), resulting in decreased 
tricarboxylic acid cycle gene, increased lactate level and 
proliferation [5].  
It has been shown that miRNAs are involved in all the 
cancer hallmarks and exhibit the potential as biomarkers for 
breast cancers. Moreover, a very recent study suggested 
profiling a cluster of miRNAs is more accurate than 
analyzing a single miRNA in clinical samples [34]. 
In the complex machinery of miRNA processing, a family 
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of proteins known as the DEAD-box RNA helicases, have 
been found to be essential. As its name suggests, DEAD-box 
RNA helicases function by unwinding double stranded RNA 
molecules, and are crucial in cellular processes involving 
RNA metabolism, including miRNA processing [35]. 
Eukaryotic DEAD-Box RNA helicases belong to the largest 
group of helicase superfamily, known as Superfamily 2 
(SF2). They are characterized by nine conserved motifs [36]; 
motif I, II, VI and Q are essential for ATP binding and 
hydrolysis, while motifs Ia, Ib, III, IV, and V are involved in 
intramolecular rearrangements and RNA interaction [37]. 
Amongst the nine conserved motifs, motif II (or Walker B 
motif) is the most characteristic, where amino acids 
D-E-A-D (asp-glu-ala-asp) are found [38].  
Several DEAD-box RNA helicases have been reported to 
regulate expression of potential oncogenic proteins through 
miRNA processing [39]. Recently, DEAD-box RNA helicase 
DDX1 was found to promote specifically, the maturation of 
miR-200 family of tumor suppressing miRNAs and in turn 
inhibit metastasis [12]. DEAD-box RNA helicase paralogs 
DDX5/DDX17 have been reported to be part of the drosha 
miRNA processor complex, processing both oncogenic (e.g. 
miR-21, miR-182 and let-7 family miRNAs) and growth 
suppressing miRNAs (e.g. miR16-1, miR-143, miR-145) in 
various cancer types [39, 40].  In addition to miRNA 
processing, Etienne et al. have also reported DDX5/DDX17 
to regulate miRNA production at transcriptional level [40]. In 
breast cancer, DDX5 was shown to directly regulate 
oncomiR-182, resulting in increased expression of cofilin 
and profilin, which are crucial for cytoskeletal reorganization 
during breast cancer invasion and metastasis [41]. RNA 
helicase, DDX6, was found to regulate miRNA processing in 
cancers, where they negatively regulate miR-143/145 
expression via post-transcriptional regulation. DDX6 
interacts with AGO1/2, components of the RNA-induced 
silencing complex (RISC) and also essential proteins for 
Dicer-independent miRNA processing [42]. From recent 
reports, DEAD-box RNA helicases play a pivotal role in 
miRNA processing and production, and these reports are 
possibly only a tip of the iceberg; it would not be surprising 
to see more association between DEAD-box RNA helicases, 
miRNA processing and cancers in the near future.  
Over the years, DEAD-box RNA helicases have been 
often associated with breast cancers, examples include: 
DDX3, DDX5/17, DDX6, DDX10, DDX21, DDX43 and 
most recently DDX20 [39, 43]. A recent study from our group 
has reported for the first time DDX20 (also known as DP103 
or Gemin 3) to be a novel onco-protein involved in breast 
cancer metastasis [43]. Expression of DDX20 was not only 
found to be significantly higher in highly metastatic triple 
negative breast cancers (TNBCs) compared to other less 
invasive subtypes, abrogating DDX20 effects via siRNA 
knockdown significantly reduced invasion and migration of 
TNBC cell lines.  
DDX20, like other DEAD-box RNA helicases in the 
family, is an important protein for RNA metabolism. One of 
the earliest reports studied the role of DDX20 in mRNA 
splicing. DDX20 has been reported to interact with proteins 
in the survival motor neurons (SMN) complex, the spinal 
muscular atrophy gene product, together with other small 
nuclear RNAs (snRNAs) and ribonucleic proteins (snRNPs), 
forming the spliceosomal complex during mRNA splicing [44, 
45]. DDX20 has also been reported in miRNA processing, 
where some reports showed its association with cancers. In 
one of the earliest reports, Mourelatos et al. showed DDX20 
as a miRNA biogenesis factor and a component of miRNP 
complex via immunoprecipitation and sucrose gradient 
centrifugation. In addition, DDX20 was found to be part of a 
complex that contains eIF2C2, a member of the Agronaute 
(ago) protein family [46]. A later study showed that DDX20 
specifically interacts with ago2 and let-7 programmed RISC 
complex, which are essential for miRNA and RNA 
interference (RNAi) formation [47]. Furthermore, Mourelatos 
et al. described a total of forty known and novel miRNAs to 
be associated with the gemin3-gemin4-eIF2C2 complex; 
examples include miR-21 to miR-23 and miR-24, miR-110 
to miR-121 [46]. In relation to cancer, Takata et al. published 
two reports describing DDX20’s role in miR-140 processing 
in hepatocellular carcinoma (HCC) [48, 49]. In the first study, 
DDX20 was found to be inversely associated with NF-κB 
activity in liver cancer cells, where reduced DDX20 
expression significantly increased NF-κB activity. DDX20 
expression is commonly found to be downregulated in HCC 
patients, it was later discovered that DDX20 interacted 
directly with miR-140 and its deficiency resulted in a defect 
in miR-140 processing and expression [49]. miRNA-140 is 
one of the critical suppressors of NF-κB activity, and its 
expression is often lost in HCC [50]. Further mechanistic 
studies found miR-140 and DDX20 deficient cells to display 
increased methylation in the CpG islands/shores of 
metallothionein (MT) promoters, mediated by DNA methyl 
transferase (Dmnt) [48].   
Interestingly, in our ongoing study, in silico analysis of the 
3’-UTR of DDX20 showed that DDX20 could be regulated 
by miR-222 in invasive breast cancers.  Many studies have 
reported the oncogenic potential of miR-221/222. In breast 
cancer, miR-221/222 has also been shown to play significant 
roles, including conferring drug resistance and promoting 
EMT [44, 50]. Notably, in our study, the effects of 
manipulation of miR-222 on DDX20 expression revealed an 
inverse correlation between miR-222 and DDX20 in breast 
cancer cells, indicating the possible tumor suppressor role of 
RNA & DISEASE 2015; 2: e846. doi: 10.14800/rd.846; © 2015 by Wanpei Cai, et al. 
http://www.smartscitech.com/index.php/rd 
 
Page 4 of 6 
 
miR-222. The tumor-suppressing effect of miR-221/222 was 
also observed in luminal invasive carcinomas, where 
miR-221/222 inversely correlates with Ki67 and the most 
high-grade tumors express low levels of miR-221/222 [51]. 
In conclusion, miRNAs are involved in different 
hallmarks of breast cancers and may be exploited for 
diagnostic and therapeutic purposes. DEAD-box RNA 
helicases have been shown to be involved in miRNA 
regulation in several cancer types (Figure 1), however, their 
roles in breast cancer remain to be explored. Our observation 
of miR-222 and DDX20 provided another dimension of the 
possible roles miRNAs and DEAD-box RNA helicases may 
play in breast cancers, where targeting miRNAs or DDX20 
for breast cancer treatment may be a possible solution in the 
future.  
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